TG Therapeutics is anticipating significant growth in its BRIUMVI U.S. net product revenue for the year 2024. Based on preliminary results, the company expects to generate approximately $41-$46 million in the first quarter of 2024 and a substantial $220-$260 million for the entire year.
These projections are built upon the company’s impressive performance in 2023, where it achieved a net product revenue of around $40 million in the fourth quarter and $89 million for the full year.
Looking ahead, TG Therapeutics has outlined its plans for 2024, which include the initiation of clinical development for subcutaneous BRIUMVI. This marks an important milestone for the company as it seeks to expand its product offerings and cater to a broader patient population.
Additionally, TG Therapeutics is set to commence a trial to evaluate the effectiveness of azer-cel in treating autoimmune diseases. This demonstrates the company’s commitment to exploring new therapeutic avenues and addressing unmet medical needs.
Overall, TG Therapeutics is poised for a promising year in 2024, with anticipated revenue growth and exciting developments in its pipeline.
[bs_slider_forecast ticker=”TGTX”]
TG Therapeutics Inc. (TGTX) Stock Price Drops by 16.52% on January 10, 2024: Analysis and Long-Term Outlook
TG Therapeutics Inc. (TGTX) experienced a significant drop in its stock price on January 10, 2024. The stock opened at $22.62, which was $1.61 higher than its previous close. However, TGTX shares quickly declined throughout the day, decreasing by $3.47 since the market last closed, resulting in a drop of 16.52%. Despite this decline, TGTX is still trading above its 200-day simple moving average, indicating relatively strong long-term performance. Additionally, TGTX is currently trading in the middle of its 52-week range. It is important to consider the broader context of the stock’s performance and conduct thorough research before making any investment decisions.
[stock_market_widget type=”chart” template=”basic” color=”#3946CE” assets=”TGTX” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” api=”yf”]
TG Therapeutics Inc. Reports Decreased Revenue but Strong Rebound in Q3 2023: A Closer Look at Financial Performance and Potential Investment Opportunities
TG Therapeutics Inc. (TGTX) is a biopharmaceutical company focused on developing and commercializing treatments for cancer and autoimmune diseases. According to data from CNN Money, TGTX reported a total revenue of $2.79 million over the past year, a decrease of 58.36% compared to the previous year. However, the company’s total revenue for the third quarter of 2023 was $165.81 million, an increase of 931.57% since the previous quarter. TGTX also reported a net loss of $198.34 million over the past year but managed to turn things around in the third quarter of 2023 with a net income of $113.93 million. The company’s earnings per share (EPS) improved from -$1.46 over the past year to $0.73 in the third quarter of 2023. These figures indicate a challenging year for TGTX in terms of total revenue but a strong rebound in the third quarter with significant growth in both total revenue and net income. The increase in net income and EPS demonstrates TGTX’s ability to improve its profitability and financial performance. Investors and analysts will closely monitor TGTX’s performance in the coming quarters to assess if the positive momentum can be sustained. It’s important to consider various factors, including market conditions and industry trends, before making any investment decisions regarding TGTX stock.
